Evidence map›Paper›PMID 29802266›Full record

ArticleScientific reports2018

Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photoreactive riluzole analog.

Peter Lukacs, Mátyás C Földi, Luca Valánszki, Emilio Casanova, Beáta Biri-Kovács, László Nyitray, András Málnási-Csizmadia, Arpad Mike

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Ligand-based pharmacophore modeling for the discovery of NaJournal of computer-aided molecular design · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Peter LukacsMTA-ELTE NAP B Opto-Neuropharmacology Group, Budapest, Hungary.
Mátyás C FöldiMTA-ELTE NAP B Opto-Neuropharmacology Group, Budapest, Hungary.
Luca ValánszkiMTA-ELTE NAP B Opto-Neuropharmacology Group, Budapest, Hungary.
Emilio CasanovaDepartment of Physiology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-7992-5361
Beáta Biri-KovácsDepartment of Biochemistry, Eötvös Loránd University, Budapest, Hungary.
László NyitrayDepartment of Biochemistry, Eötvös Loránd University, Budapest, Hungary.
András Málnási-CsizmadiaDepartment of Biochemistry, Eötvös Loránd University, Budapest, Hungary.
Arpad MikeMTA-ELTE NAP B Opto-Neuropharmacology Group, Budapest, Hungary. arpadmike1@gmail.com.
Eötvös Loránd University · HUComprehensive Cancer Center Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium channel inhibitor drugs decrease pathological hyperactivity in various diseases including pain syndromes, myotonia, arrhythmias, nerve injuries and epilepsies. Inhibiting pathological but not physiological activity, however, is a major challenge in drug development. Sodium channel inhibitors exert their effects by a dual action: they obstruct ion flow ("block"), and they alter the energetics of channel opening and closing ("modulation"). Ideal drugs would be modulators without blocking effect, because modulation is inherently activity-dependent, therefore selective for pathological hyperactivity. Can block and modulation be separated? It has been difficult to tell, because the effect of modulation is obscured by conformation-dependent association/dissociation of the drug. To eliminate dynamic association/dissociation, we used a photoreactive riluzole analog which could be covalently bound to the channel; and found, unexpectedly, that drug-bound channels could still conduct ions, although with modulated gating. The finding that non-blocking modulation is possible, may open a novel avenue for drug development because non-blocking modulators could be more specific in treating hyperactivity-linked diseases.

Indexed as

Ultraviolet RaysAnimalsAzidesCHO CellsCricetulusDose-Response Relationship, DrugIon Channel GatingMuscle ProteinsRatsRiluzoleSodium Channel BlockersSodium ChannelsAzidesMuscle ProteinsRiluzoleScn4a protein, ratSodium Channel BlockersSodium Channels

Identifiers

PMID29802266
PMCPMC5970139
OpenAlexW2952622138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.